Purdue Pharma

Critics say the settlement doesn't hold company executives or members of the Sackler family accountable for their aggressive marketing of OxyContin, which helped fuel the nation's opioid epidemic.

The nation's three dominant drug distributors and a big drugmaker have reached a $260 million deal to settle a lawsuit related to the opioid crisis just…

The largest-ever federal action concerning the U.S. opioid crisis has only gotten more complicated amid a slew of recent settlements. So here's a brief(ish) explainer breaking it down.

"The Sackler family does not belong in bankruptcy court," Rep. Max Rose said of Purdue Pharma's owners. "They belong in handcuffs." He and others want charges for drug companies linked to the crisis.

In the 15 years since she lost her son to a single OxyContin pill, Barbara Van Rooyan has had but one up-close look at the people representing the company…

The bankruptcy follows the Sackler family, which owns Purdue, agreeing to surrender control of the company and offering $3 billion in cash to opioid-hit communities.

The pending settlement likely means Purdue will avoid going to trial in the sprawling and complicated case involving some 2,300 local governments across 23 states.

OxyContin maker Purdue Pharma reached a tentative deal Wednesday with about half the states and thousands of local governments over its role in the...

A group of state attorneys general negotiating with members of the Sackler family says they expect Purdue Pharma to file for bankruptcy "imminently," according to an email obtained by NPR.

Lawsuits over the way drugmakers have marketed opioids are already putting a dent in companies' reputations. Litigation has forced the release of internal documents that are shifting the narrative.